Cancer, Covid19
Conditions
Keywords
Cancer, Covid-19, Vaccine
Brief summary
The aim of the study is to evaluate the effects and side effects of inactive COVID-19 vaccine in patients with cancer and compare them with the healthy control group.
Detailed description
The aim of the study is to evaluate the effects and side effects of inactive COVID-19 vaccine in patients with cancer. Patients followed up in medical oncology clinic and healthy volunteers will be enrolled in the study. Blood samples of participants will be taken 4 weeks after the second dose of the COVID-19 vaccine. After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different eppendorf tubes and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples. In addition, volunteers will be questioned in terms of side effects that may develop after vaccination and the information obtained will be recorded in the database together with the clinical data of the patients.
Interventions
5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
Sponsors
Bezmialem Vakif University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Intervention model description
The study consists of two groups : 1) Cancer patients, 2) Healthy controls Blood samples will be taken from the participants of the two groups 4 weeks after the second dose of the COVID-19 vaccine and antibody testing will be performed. Additionally participants will be questioned for side effects of the vaccine and the data will be registered.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
For the patient group : 1. Patients with pathological and clinical cancer diagnosis 2. Older than 18 years 3. Patients two doses of COVID-19 vaccine administered 4. Volunteering to participate in the study For the control group : 1. No known cancer diagnosis or history 2. Older than 18 years 3. Two doses of COVID-19 vaccine administered 4. Volunteering to participate in the study -
Exclusion criteria
1. Not volunteering to participate in the study 2. \< 18 years 3. Not administered two doses of the COVID-19 vaccine 4. Covid-19 infection history -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antibody levels | 1 month | COVID-19 antibody titers of the patients will be measured in blood samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side effects | 1 month | Participants will be questioned for common side effects |
Countries
Turkey (Türkiye)
Outcome results
None listed